Attached files

file filename
EX-10.1 - EXHIBIT 1-.1 - MultiCell Technologies, Inc.v236604_ex10-1.htm



UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549

 


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

September 30, 2011


 

MULTICELL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
 
001-10221
 
52-1412493
(State or other jurisdiction of incorporation)
 
(Commission  File Number)
 
(IRS Employer
Identification No.)

68 Cumberland Street, Suite 301
Woonsocket, Island 02895
 (Address of principal executive offices, including zip code)

(401) 762-0045
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

Item 1.01          Entry Into a Material Definitive Agreement.

On September 30, 2011, Multicell Technology, Inc., or the Company, entered into an amendment to the Foreclosure Sale Agreement, or the Agreement, dated as of September 30, 2010, by and among Xenogenics Corporation, Venture Lending & Leasing IV, Inc., Venture Lending & Leasing V, Inc. and Silicon Valley Bank.  The amendment extends deadlines for the achievement of certain milestones under the Agreement by twelve months.

The foregoing description of the amendment and the Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the amendment, a copy of which is attached hereto as Exhibit 10.1 to this Current Report on Form 8-K, and the full text of the Agreement, which was filed as exhibit 10.2 to a Current Report on Form 8-K filed on October 20, 2010.  The foregoing exhibits are hereby incorporated by reference.


Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
Description
   
10.1
Amendment to Foreclosure Sale Agreement, dated as of September 30, 2010, by and among Xenogenics Corporation, Venture Lending & Leasing IV, Inc., Venture Lending & Leasing V, Inc. and Silicon Valley Bank, dated as of September 30, 2011.

 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
MULTICELL TECHNOLOGIES, INC.
     
 
By:
/s/ W. Gerald Newmin
 
   
W. Gerald Newmin
Chief Executive Officer, Chief Financial Officer

Date:  October 6, 2011